







Pancreatic ductal adenocarcinoma (PDAC) is the most 
common cancer of the exocrine part of the pancreas, 
with poor prognosis, accounting for more than 90% 
of cases [1].
Pancreatic ductal adenocarcinoma is the 11th most 
common human cancer worldwide and the 7th most 
common cancer in western countries [2].
In Poland, 3486 cases of PDAC were reported in 2016, 
representing approximately 2% of all cancers diagnosed 
in our country [3].
Pancreatic ductal adenocarcinoma belongs to a small 
group of cancers with an increasing incidence rate 
(1–2% per year for more than a decade). Additionally, 
it has one of the lowest overall 5-year survival rates, 
currently at 9% [4]. 
There is an alarming prognosis that by 2030 PDAC 
will be the second cancer for mortality in the US [5].
The main risk factors for PDAC are tobacco smok-
ing, alcohol consumption, obesity, and type 2 diabetes; 
others are also suspected, such as dietary factors and 
allergy [6].
Type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) is the third modifiable 
risk factor for PDAC after smoking and obesity [7]. 
T2DM is defined as a group of metabolic diseases 
characterized by hyperglycaemia due to a defect of 
insulin secretion and/or its action. The main cause of 
T2DM is a progressive impairment of insulin secretion 
by b cells and insulin resistance in various tissues, e.g. 
skeletal muscles, adipocytes, and liver. Dysfunction 
of b cells is associated with the complex interactions 
between environmental and molecular factors, such 
as hyperglycaemia, hyperlipidaemia, and chronic in-
flammation, which can induce a loss of pancreatic islet 
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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is the most common cancer of the exocrine part of the pancreas, with poor prognosis. Up to 
85% of PDAC patients are diagnosed with diabetes or hyperglycaemia at the time of cancer diagnosis. It indicates that impaired glucose 
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influence of insulin treatment on the risk of PDAC is assessed as unclear. A recent analysis showed that this risk is higher in patients with 
new-onset diabetes. Insulin analogues were reported to be associated with PDAC, but recent trials did not confirm a significantly higher 
cancer risk. Metformin, recommended as the first-choice therapy in type 2 diabetes, possesses anti-cancer activity and can prolong the 
survival of PDAC patients. In can be used in monotherapy or with other antidiabetic drugs, such as SGLT-2 inhibitors, incretins, sulphonyl-
ureas, or thiazolidinediones. SGLT-2 inhibitors may be protective in PDAC by inhibiting tumour growth. Incretin-based therapy appears 
to have a beneficial effect in PDAC patients even after long-term therapy. Sulphonylureas and alpha-guanidine inhibitors are associated 
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ENDPAC (Enriching New-Onset Diabetes for Pancreatic 
Cancer) model was developed to determine the risk of 
PC in patients with NOD. It includes 3 factors identified 
in the cohort as most strongly associated with PDAC: 
(1) change in body weight, (2) change in blood glucose 
levels, and (3) age at onset of diabetes. The ENDPAC 
model attributes patients with NOD to 3 groups, based 
on 3-year pancreatic cancer risk: low (< 0.1%), interme-
diate (about 0.5%), and very high (about 4%). Based on 
glycaemic status, the ENDPAC model can help identify 
75% of PDAC patients with NOD 6 months before the 
cancer diagnosis [15]. 
The mechanism of association between PDAC and 
diabetes is very complex and still not fully understood. 
Insulin receptors share significant homology and similar 
signalling pathways with insulin growth factor 1 (IGF-1) 
receptor; thus, IGF-1 can bind to insulin receptor and 
then stimulate cell proliferation [16]. 
Insulin has mitogenic activity and can stimulate 
cell growth without malignant transformation. But the 
hormone can also stimulate the growth of transformed 
cells and thus increase the incidence of tumour develop-
ment. It has been suggested that a direct effect of insulin 
especially in hyperinsulinaemia could partly explain the 
increased incidence of cancer [17].
In the development of PDAC on the basis of diabe-
tes, as in pathological obesity, the most important factor 
is the long-term persistence of high intra-pancreatic 
insulin concentrations. Augmented intra-pancreatic 
insulin is a consequence of continuous stimuli flowing 
to the b cells resulting from the peripheral insulin resis-
tance. The hormone released by b cells arrives with the 
blood via the intra-pancreatic portal circulation to the 
follicular and ductal cells adjacent to the islets. Insulin 
molecules released in excess activate insulin receptors 
present on the surface of papillary cells and any trans-
formed cells that may arise in this region, promoting 
their survival and proliferation. Thus, particularly 
intra-pancreatic hyperinsulinaemia, resulting from 
obesity and insulin resistance in pre-diabetes or early 
diabetes, is likely to contribute to the observed increased 
risk of PDAC [11].
Moreover, the increased availability of glucose or 
lipids observed in diabetes and obesity is responsible 
for the increased synthesis of highly reactive carbonyl 
compounds, a condition referred to as ‘carbonyl stress’. 
These compounds, also known as glycotoxins and lipo-
toxins, rapidly react and damage various molecules in 
cells, forming end products known as AGEs (advanced 
glycation end-products). AGEs were shown to sig-
nificantly accelerate tumour growth in an experimental 
pancreatic cancer model, while inhibition of AGEs pre-
vented the cancer-promoting effect of diabetes. These 
results suggest that carbonyl stress is involved in cancer 
integrity and apoptosis. Moreover, the disturbances in 
the synthesis and secretion of insulin and its precursors 
and a reduced expression of glucose transporters can 
contribute to diabetes foundation [8].
Chronic hyperglycaemia leads to the develop-
ment of micro- and macrovascular complications and 
is associated with a failure of various organs, such 
as eyes, kidneys, nerves, blood vessels, and heart. 
Diagnostic criteria of diabetes include the following: 
symptoms of hyperglycaemia and random blood 
glucose level ≥ 200 mg/dL (≥ 11.1 mmol/L), fasting 
blood glucose level (FGL) ≥ 126 mg/dL (≥ 7.0 mmol/L) 
on two occasions, blood glucose at 120 minutes of 
OGTT ≥ 200 mg/dL (≥ 11.1 mmol/L), and glycated hae-
moglobin (HbA1c) level ≥ 6.5% [9, 10].
The incidence of diabetes in PDAC is higher than 
the occurrence of diabetes in a group of other can-
cers. Moreover, the main risk factors for T2DM such as 
age, obesity, and a family history of diabetes are also 
risk factors for PDAC [11].
Up to 85% of PDAC patients are diagnosed with 
diabetes or hyperglycaemia at the time of diagnosis, in-
dicating that impaired glucose homeostasis is a common 
event in this cancer. In a population-based cohort study 
of US PDAC patients (n = 219), it was reported that 
42% of them met the American Diabetes Association 
criteria for diabetes. Among them, 52% had new-onset 
diabetes (NOD), 13% had advanced pre-diabetes – as 
indicated by FGL ≥ 120 mg/dL, 21% had an abnormal 
FGL, and only 9% had a normal FGL at the time of 
cancer diagnosis [12].
A prospective study of 512,000 adult people and 
a meta-analysis of 22 cohort studies found that in Chi-
nese and non-Chinese populations, not only diabetes 
but also hyperglycaemia in both people with and with-
out diabetes were associated with an increased risk of 
PDAC. Among individuals without diabetes, for every 
1 mmol/L higher blood glucose level, there was a 15% 
increase in PDAC risk [13].
Epidemiological studies revealed that long-standing 
type 2 diabetes mellitus (LSDM) is associated with a 1.5- 
to 2.0-fold increase in the risk of PDAC [7].
Patients with newly diagnosed diabetes have as 
much as a 5–8-fold increased risk of being diagnosed 
with PDAC within 1–3 years of onset [14]. 
Because LSDM is a risk factor for PDAC and, con-
versely, PDAC in many cases is a putative cause of new 
onset diabetes (NOD), diabetes and PDAC are consid-
ered to exhibit “dual causality”. But the mechanisms 
of these associations are unclear, as are the diagnostic 
criteria to distinguish LSDM from diabetes that occurrs 
as an early event of PDAC [11].
Among NOD patients over the age of 50 years, PDAC 
is diagnosed in approximately 1% within 3 years. The 
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development and growth and potentially links diabetes 
and PDAC, providing a target for drugs [18].
Additionally, evidence of an association between 
hyperglycaemia and genomic instability has recently 
been found in pancreatic cancer. High glucose level can 
increase post-translational O-GlcNAcylation, leading to 
nucleotide imbalance and genomic instability support-
ing KRAS mutations [19].
Another possible mechanism that can influence the 
development of PDAC is associated with cancer stem 
cells (CSC). They are supposed to account for tumour 
initiation, progression, recurrence, and therapy resis-
tance due to their unique ability to self-renew and give 
rise to differentiated cells, as well as their profound 
survival strategies.  A study on pancreatic cancer cell 
lines (Panc 1) showed that hyperglycaemia promotes 
the acquisition of mesenchymal and CSC properties in 
PDAC by activating TGF-b signalling and might explain 
how T2DM facilitates pancreatic tumourigenesis [20].
Antidiabetic drugs
Currently, various classes of antidiabetic drugs are used 
in diabetes management. The most often applied drugs 
include insulin and insulin analogues, biguanides, 
sodium-glucose co-transporter-2 (SGLT-2) inhibitors, 
glucagon-like peptide-1 (GLP-1) agonists, dipeptidyl 
peptidase-4 (DPP-4) inhibitors, sulphonylureas, thia-
zolidinediones, and alpha glucosidase inhibitors. 
Insulin and insulin analogues
Insulin therapy is the oldest form of treatment for 
diabetes administered both in type-1 and type-2 of the 
disease. Besides lowering the glucose level in blood, 
insulin can act as a growth factor and cause a prolifera-
tion and transformation of various cells [17].
Insulin analogues are synthesized by modification of 
amino acids in the insulin chain, which allows the creation 
of rapid (e.g. lispro) and long-acting (e.g. glargine) drugs.
A comparison of insulin with its analogues found 
that the analogues had a higher IGF-1 receptor affinity 
and also a lower differentiation rate than the human 
insulins [21].
In physiological conditions insulin is released 
from the pancreas into the portal vein, and it reaches 
hepatocytes, where inhibits gluconeogenesis and gly-
colysis. Insulin analogues administered subcutaneously 
are bound to serum proteins and then released in the 
peripheral tissue/adipose tissue and muscles [22].
Earlier studies proved that diabetic patients treated 
with insulin had a significantly higher risk of pancreatic 
cancer than patients treated with other hypoglycaemic 
agents [23].
In newer studies the effect of insulin on the risk of 
PDAC in patients with T2DM was assessed as unclear; 
a short period of insulin use (< 5 years) significantly 
increased PDAC risk, while a longer period (> 15 years) 
did not [24]. 
Moreover, there is no evidence that the insulin ana-
logues have a higher mitogenic potential than a human 
insulin. The long-term, randomized control ORIGIN 
(Outcome Reduction with an Initial Glargine Interven-
tion) trial did not demonstrate an increased risk of any 
cancer in patients using glargine [25].
A recent analysis showed that the risk of PDAC 
associated with insulin therapy is dependent not so 
much on the type of the drug but more on the diabetes 
subtype. This risk is higher in patients with the NOD 
diabetes subtype than in the LSDM subgroup. An 
explanation for this phenomenon is related to the fact 
that in the NOD, insulin treatment was started earlier 
due to a faster or more aggressive disease progression, 
consequently leading to b-cell dysfunction, impaired 
proinsulin processing, and the development of insulin 
resistance [26].
Biguanides
Biguanides are derivatives of guanidine. Nowadays, 
a representative of, and the only available drug from, 
this group is metformin. For many years metformin 
has been the gold standard in the treatment of type 2 
diabetes. According to recommendations from the most 
important diabetes associations, this is the first-choice 
drug for use as monotherapy in patients with newly 
diagnosed T2DM [8, 27].  
Metformin acts as a glucose-lowering agent through 
the inhibition of hepatic glucose synthesis and an aug-
mentation of peripheral glucose uptake in the skeletal 
muscles and fatty tissue. Additionally, it is safe and 
cost-effective [28-30].
Antidiabetic effects of metformin result mainly from 
the influence on a pathway of enzyme AMP-activated 
protein kinase (AMPK) that is a regulator of the glu-
cose, lipids, and protein metabolism in the cell. It was 
proven that phosphorylation of AMPK is required for 
metformin’s inhibitory effect on glucose production 
by hepatocytes and its uptake by skeletal muscles [31].
Moreover, metformin can suppress inflammation by 
changes in the cytokine level in blood and inhibition of 
the differentiation of monocytes into macrophages. The 
latest observations show that the drug can modify 
a microbiome in the intestine and thus enhance glucose 
intestinal absorption and utilization in enterocytes, 
which can limit the access of glucose to the blood [32].
Experimental studies have described the mechanism 
by which metformin may reduce the risk of PDAC and 
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improve the survival of patients with coexisting glucose 
tolerance impairment. Primarily, it decreases insu-
lin/IGF signalling, disrupting mitochondrial respiration 
and inhibiting the mammalian target of rapamycin 
(mTOR) pathway. Other potential anti-cancer activities 
of metformin include its ability to affect transcription 
factors of specific proteins and related genes, alter 
microRNAs, reduce cancer stem cell proliferation, and 
decrease DNA damage, as well as inhibit inflammatory 
responses [33]. 
Recently, many papers have been published examin-
ing the risk of PDAC in patients with T2DM treated with 
metformin. While much evidence has been presented to 
suggest an anti-cancer effect of metformin, the results 
of clinical work often provide conflicting information.
A Polish clinical trial [34] as well as a recent large 
meta-analysis [35] that included 67 articles (10,695,875 
people with diabetes, including 145,108 cases of cancer) 
showed that metformin may be an independent protec-
tive factor against cancers, including pancreatic cancer, 
in patients with T2DM. 
Other clinical trials have shown that metformin can 
prolong the survival of PDAC patients who were treated 
with this drug prior to cancer diagnosis [36]. 
However, in a cohort study involving 66,627 pa-
tients (including 29,974 using metformin), there was 
no statistical difference compared to the control group 
(n = 36,653) in the incidence of PDAC in diabetic pa-
tients [37].
Another meta-analysis showed a beneficial role of 
metformin, although data from randomized controlled 
trials did not support these results [38]. 
A possible explanation for the differences in the 
results, particularly of cohort studies conducted by 
different teams on the relationship between metformin 
and PDAC survival, may be the high heterogeneity of 
the analysed data [39].
It is important to recognize that newer and better 
designed studies have weakened the previously strong 
evidence for reduced PDAC risk among people with 
type 2 diabetes using metformin [40]. 
Nowadays, there are also increasing attempts to use 
metformin not only in cancer prevention and treatment 
but also to decrease the mortality among people with 
diabetes and concurrent COVID-19 disease [41, 42]. 
If metformin monotherapy is not tolerated or 
contraindicated, other antidiabetic drugs should be 
applied [8].
Sodium-glucose co-transporters-2 (SGLT-2) 
inhibitors
Sodium-glucose cotransporter-2 (SGLT2) proteins are 
expressed in the proximal tubule of the kidneys, and 
they are responsible for approximately 90% of filtered 
glucose reabsorption. SGLT-2 inhibitors (e.g. dapa-
gliflozin, empagliflozin) act through a mechanism of 
reducing renal tubular glucose reabsorption and pro-
ducing a reduction in the blood glucose level without 
stimulating insulin release. Other benefits may include 
favourable effects on blood pressure and weight, so 
SGLT2 inhibitors may be a useful option in obese and 
hypertensive patients [43]. 
The expression of SGLT2 can be up-regulated in 
patients with T2DM, causing an inadequate response 
that deteriorates hyperglycaemia [44].
They can be combined with metformin [8] or applied 
as a second-line treatment when other antidiabetic 
drugs did not provide adequate glycaemia [22]. 
Tang et al., in a systematic review and meta-analysis 
of 35 randomized trials (including 44912 patients), did 
not find an association between SGLT2 inhibitors and 
increased risk of PDAC in patients with T2DM. More-
over, they might be protective in PDAC by inhibiting 
tumourigenesis and could be a potential target in 
therapy [45].
Incretins
GLP-1 (glucagon-like peptide-1) and DPP-4 (dipep-
tyl-peptidase-4) are secreted from enteroendocrine 
cells of the intestine after eating and then stimulate 
the pancreas to release insulin together with hypergly-
caemia (the incretin effect). In physiological conditions 
GLP-1 can also suppress appetite and the synthesis of 
glucose in the liver. GLP-1 can be degraded by enzyme 
DPP-4. Agonists of GLP-1 (e.g. dulaglutide, liraglutide) 
and inhibitors of DPP-4 (e.g. sitagliptin, linagliptin) 
are insulinotropic factors, and they can stimulate the 
secretion of insulin induced by glucose and inhibit the 
release of glucagon [22].
The main advantage of these drugs is the lack of 
increased risk of hypoglycaemic episodes, and without 
weight gain [46]. 
Currently, incretins can be applied as first-line treat-
ment if there is an intolerance or contraindication to 
metformin therapy [47].
A large meta-analysis based on six prospective ran-
domized controlled trials (EXMAINE, ELIXA, LEADER, 
SAVOR-TIMI53, SUS-TAIN-6, LEADER, and TECOS) 
with 55,248 patients with T2DM using incretin-based 
drugs revealed no significant effects on the risk of car-
diovascular and pancreatic diseases (acute pancreatitis 
and pancreatic cancer) [48]. 
Similarly, a study published in 2019 based on a large 
database of randomized, placebo-controlled, prospec-
tive cardiovascular outcome studies with GLP-1 recep-
tor agonists and DPP-4 inhibitors found no association 
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between this group of drugs and the risk of pancreatic 
and other cancers after long-term therapy [4According 
to a recent meta-analysis, the association between the 
use of DPP-4 inhibitors and the risk of PDAC in patients 
with T2DM was also not confirmed [50, 51].
Sulphonylureas
Sulfonylureas (Sus) (e.g. glibenclamide, glimepiride) 
increase insulin secretion from pancreatic b cells in 
a non-glucose-dependent manner.  They bind to the 
receptor SUR (sulphonylurea receptor) subunit of the 
ATP-sensitive potassium channel (KATP) and then can 
inhibit the channel. Such inhibition causes changes in 
depolarization of the beta-cell membrane, and stimu-
late influx of Ca2+ and release of the hormone from 
granules [52].
Sulphonylureas also have various extrapancreatic 
effects such as reducing secretion of glucagon and 
insulin clearance rate in the liver and enhancing 
peripheral tissue sensitivity to insulin. The main side 
effect of Sus is increased risk of hypoglycaemia due 
to their glucose-independent action as insulin secre-
tagogues [53]. 
A few prospective and randomized controlled stud-
ies (e.g. the ADVANCE trial) have shown that use of SUs 
did not increase the all-cancer risk in T2DM patients 
compared to T2DM patients not using Sus [54–56].
Ye et al. in a population-based cohort study estimat-
ed the pancreatic cancer risk in 653 new-onset T2DM 
patients using Sus and revealed that sulphonylureas 
monotherapy was associated with significantly lower 
risk of pancreatic cancer [57].
Dankner et al., in a review of the scientific literature 
concerning an association between the use of various 
antidiabetic medications and risk of any cancer, con-
firmed that Sus had no influence on the risk of pancre-
atic cancer in patients with T2DM [40].
Meglitinides (e.g., repaglinide and nateglinide) are 
non-sulfonylurea secretagogues that share the same 
mechanism as that of sulfonylureas, but the binding 
to the receptor is weaker than with SUs. Meglitinides 
are short-acting anti-diabetic agents and play valu-
able roles in lowering postprandial hyperglycaemia 
and reducing hypoglycaemia. They can be applied 
in patients with irregular meal schedules or those 
who develop late postprandial hypoglycaemia while 
using SUs [58]. 
Li et al., in a case-control study involving 973 pa-
tients with PDAC (including 259 diabetic patients) and 
863 controls (including 109 diabetic patients), revealed 
that insulin secretagogues (SUs and meglitinides) used 
as a monotherapy showed the highest risk of PDAC. The 
risk of PDAC was increased in short-term users but not 
in long-term users of insulin secretagogues compared 
with never users [59]. 
Thiazolidinediones
These are a group of anti-diabetic drugs that bind to 
a specific receptor — PPARg (peroxisome-proliferator 
activated receptor gamma) — and can regulate glucose 
homeostasis in blood. Beneficial effects of PPARg ago-
nists include lowering of postprandial and fasting glu-
cose level, an improvement of b-cell function and lipid 
profile in blood, as well as lowering of blood pressure 
and microalbuminuria. Additionally, they are safe and 
well tolerated, but a major drawback is non-intentional 
body weight gain. 
Thiazolidinediones can also improve b-cell func-
tion and insulin resistance in peripheral tissues and 
the liver [60, 61]. 
Pioglitazone is the only drug from this group used 
globally, because others are associated with a risk of 
hepatotoxicity and cardiovascular disease [62].
Only in one study was treatment with pioglitazone 
associated with an increased risk of pancreatic cancer 
[63].
Alpha-glucosidase inhibitors
Alpha-glucosidase inhibitors (AGIs) can delay the ab-
sorption of glucose and other carbohydrates in the small 
intestine by competitive and reversible inhibition of the 
enzyme alpha-glucosidase. Acarbose is a representative 
drug of AGIs, but also miglitol and vioglibose are used 
for glycaemic control. AGIs are safe and effective both 
in geriatric and younger patients, but the limitation for 
wider use of these drugs is poor tolerability, with side ef-
fects from the GI tract (diarrhoea, abdominal pain) [64].
A meta-analysis of 1399 studies showed that this 
group of drugs is associated with a reduced risk of 
PDAC in diabetic patients, probably by lowering the 
insulin level in blood [65].
Conclusions
A strategy for clinical management to improve the 
outcome of diabetic patients with PDAC has not been 
established so far. Antidiabetic therapy should be indi-
vidualized considering the effectiveness of lowering 
blood glucose levels, risk of hypoglycaemia, cardio-
vascular and renal risk, influence on body weight, and 
possible side effects.  Moreover, the intriguing question 
of whether diabetes can facilitate PDAC development 
remains unanswered.  Currently, targeted diagnostic 
and therapeutic strategies are needed to improve the 
poor survival rates for diabetic patients with PDAC.
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